HCPCS 2022

(7)
HCPCS 2022 image
ISBN-10:

157066143X

ISBN-13:

9781570661433

Author(s): James B. Davis
Released: Nov 15, 2021
Format: Perfect Paperback, 749 pages

Description:

Maximize your Medicare reimbursement by using the most current HCPCS Level II codes. These codes must be used to bill Medicare for supplies, materials, injections, DME, rehab, and other services. Our HCPCS includes exclusive features such as thumb indexing, new lay-flat binding and color coding, all designed to make coding faster and easier. Includes all official HCPCS Level II codes with full descriptions, table of drugs, index and appendices Includes National Coverage Determinations Manual (NCD)and Medicare Carriers Manual (MCM) citations plus the full text of the references in an appendix Code more accurately with our color-coding and symbol notation system Locate codes faster with our exclusive thumb indexing Lays flat on your desk and stays open during use Approved for all certification exams

Best prices to buy, sell, or rent ISBN 9781570661433




Frequently Asked Questions about HCPCS 2022

You can buy the HCPCS 2022 book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $39.83 on Amazon and is available from 6 sellers at the moment.

At BookScouter, the prices for the book start at $3.98. Feel free to explore the offers for the book in used or new condition from various booksellers, aggregated on our website.

If you’re interested in selling back the HCPCS 2022 book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the HCPCS 2022 book, the best buyback offer comes from and is $ for the book in good condition.

The HCPCS 2022 book is in very low demand now as the rank for the book is 5,683,819 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.